Dolly Quispe Leveau, MD
Hematology & Oncology · Fort Wayne, INNPI 1821209370
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $65,498 of the $73,716 with a category attached, or 88.9%. Daiichi Sankyo Inc. accounts for 73.1% of it on its own, with 58 other manufacturers making up the rest. Reporting peaked in 2020 at $47,696 and has fallen 96.5% since, to $1,657 in 2025. Among hematology & oncology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 320 payments — averaging $230.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$54K
- Astellas Pharma US Inc$12K
- Johnson & Johnson$1K
- Merck$453
- Pfizer$434
- Pharmacyclics LLC, An Abbvie Company$415
- plus $6K from 53 others
What the payments were for
- Consulting fees$65,49889%
- Speaking & faculty fees$5001%
- Food & beverage$6,7979%
- Education$9201%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$73,716 in reported general payments places this provider in the 90th percentile of 224 hematology & oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OjjaaraMomelotinib Dihydrochloride | 13 | $349,296 |
| JakafiRuxolitinib Phosphate | 21 | $344,137 |
| TagrissoOsimertinib Mesylate | 15 | $249,092 |
| TasignaNilotinib Hcl | 11 | $109,467 |
| EliquisApixaban | 73 | $67,049 |
| XareltoRivaroxaban | 23 | $29,391 |
| Fondaparinux Sodium | 11 | $7,098 |
| Anastrozole | 109 | $2,560 |
| Letrozole | 24 | $2,091 |
| Exemestane | 16 | $1,975 |
| Morphine Sulfate ErMorphine Sulfate | 11 | $405 |
| Hydroxyurea | 24 | $386 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 15 | $344 |
| Dexamethasone | 13 | $283 |
| Gabapentin | 11 | $269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $32 | $344,13721 claims |
| AstraZenecaTagrisso | $320 | $249,09215 claims |
| NovartisTasigna | $303 | $109,46711 claims |
| PfizerEliquis | $434 | $67,04973 claims |
| Johnson & JohnsonXarelto | $1,031 | $29,39123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 224 hematology & oncology providers in Indiana.
Other hematology & oncology in Fort Wayne
- Ahad SadiqFort Wayne$430K
- Zhentao ZhangFort Wayne$167K
- Sreenivasa NattamFort Wayne$120K
- Praveen KolliparaFort Wayne$88K
- Matthew CarrFort Wayne$51K
- Shalini ChitneniFort Wayne$46K
- Ryan GonzalesFort Wayne$38K
- Robert MangesFort Wayne$31K
- Michael TooleFort Wayne$27K
- Melanie ClarkFort Wayne$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.